Influence of ligand binding kinetics on functional inhibition of human recombinant serotonin and norepinephrine transporters

Journal of Pharmacological and Toxicological Methods

Volumn 61, Issue 2, 2010, Pages 192-204

  Tsuruda, Pamela R ^a   Yung, Joey ^a   Martin, William J ^a   Chang, Ray ^a   Mai, Ngoc ^a   Smith, Jacqueline A M ^a  

^a THERAVANCE INC   (United States)

Author keywords

Binding kinetics; LeuT; Mode of inhibition; Monoamine reuptake inhibitor; NET; Neurotransmitter uptake methods; SERT; SLC6 transporter; Time dependent inhibition

Indexed keywords

1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE; ATOMOXETINE; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; ESREBOXETINE; MILNACIPRAN; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PROTEIN BINDING; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIGAND BINDING;

ADRENERGIC UPTAKE INHIBITORS; ALGORITHMS; BINDING SITES; CELL LINE; FLUORESCENT DYES; HUMANS; KINETICS; LIGANDS; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROTEIN BINDING; RADIOLIGAND ASSAY; RECOMBINANT PROTEINS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TEMPERATURE;

EID: 77950539781     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2009.12.003     Document Type: Article

References (34)

1. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control 1974, 19(6):716-723.
2. Andersen J., Taboureau O., Hansen K.B., Olsen L., Egebjerg J., Strømgaard K., et al. Location of the antidepressant binding site in the serotonin transporter: Importance of Ser-438 in recognition of citalopram and tricyclic antidepressants. The Journal of Biological Chemistry 2009, 284(15):10276-10284.
3. Andreeta, F., Hildick, K., Kelly, J.S., Negri, M., Simeoni, E., & Wren, P. (2007). Kinetics of reboxetine at the [3H]nisoxetine binding site in recombinant cell membranes. From the Brighton Winter Meeting, December 2007. Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol5Issue2abst055P.pdf.
4. Andreetta, F., Kay, L., Negri, M., Benedetti, R., Antolini, M., Faedo, S., et al. (2006). Comparative binding kinetics of [3H]DASB at human, baboon and rat 5-HT transporters. From the BPS 75th Anniversary Meeting, University of Oxford, December 2006. Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol4Issue2abst049P.pdf.
5. Apparsundaram S., Stockdale D.J., Henningsen R.A., Milla M.E., Martin R.S. Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism. The Journal of Pharmacology and Experimental Therapeutics 2008, 327(3):982-990.
6. Barker E.L., Kimmel H.L., Blakely R.D. Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Molecular Pharmacology 1994, 46(5):799-807.
7. Beuming T., Knizeff J., Bergmann M.L., Shi L., Gracia L., Raniszewska K., et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nature Neuroscience 2008, 11(7):780-789.
8. Bingham M., Napier S. Overview: Transporters as targets for drug discovery. Topics in Medicinal Chemistry 2009, 4:1-3.
9. Butt, R.P., Rees, H., Suzuki, R., Monhemius, R., Benson, N., Snelder, N., et al. (2007). An integrated pharmacological approach to describe the mechanism of action of the noradrenaline re-uptake inhibitor, SS-reboxetine. Program number 181.14/NN11. 2007 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2007. Online.
10. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology 1973, 22(23):3099-3108.
11. Elfving B., Bjørnholm B., Ebert B., Knudsen G.M. Binding characteristics of selective serotonin reuptake inhibitors with relation to emission tomography studies. Synapse 2001, 41(3):203-211.
12. Assay Guidance Manual Version 5.0 2008, Eli Lilly and Company, NIH Chemical Genomics CenterNIH Chemical Genomics Center, Available online at: http://www.ncgc.nih.gov/guidance/manual_toc.html, (last accessed October 27, 2009.
13. Huang Y., Hwang D.-R., Narendran R., Sudo Y., Chatterjee R., Bae S.-A., et al. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. Journal of Cerebral Blood Flow & Metabolism 2002, 22:1377-1398.
14. Jørgensen S., Nielsen E.Ø., Peters D., Dyhring T. Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity. Journal of Neuroscience Methods 2008, 169(1):168-176.
15. Mantovani M., Dooley D.J., Weyerbrock A., Jackisch R., Feuerstein T.J. Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytrptamine transporters in rat and human neocortical synaptosomes. British Journal of Pharmacology 2009, 158(7):1848-1856.
16. Martin R.S., Henningsen R.A., Suen A., Apparsundaram S., Leung B., Jia Z., et al. Kinetic and thermodynamic assessment of binding of serotonin transporter inhibitors. The Journal of Pharmacology and Experimental Therapeutics 2008, 327(3):991-1000.
17. Mason J.N., Deecher D.C., Richmond R.L., Stack G., Mahaney P.E., Trybulski E., et al. Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. The Journal of Pharmacology and Experimental Therapeutics 2007, 323(2):720-729.
18. Millan M.J., Gobert A., Lejeune F., Newman-Tancredi A., Rivet J.M., Auclair A., et al. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. The Journal of Pharmacology and Experimental Therapeutics 2001, 298(2):565-580.
19. Motulsky H.J., Mahan L.C. The kinetics of competitive radioligand binding predicted by the law of mass action. Molecular Pharmacology 1984, 25(1):1-9.
20. Mullins D., Adham N., Hesk D., Wu Y., Kelly J., Huang Y., et al. Indentification and characterization of pseudoirreversible nonpeptide antagonists o the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand. European Journal of Pharmacology 2008, 601(1-3):1-7.
21. Nightingale B., Dersch C.M., Boos T.L., Greiner E., Calhoun W.J., Jacobson A.E., et al. Studies of the biogenic amine transporters. XI. Identification of a 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) analog that allosterically modulates the serotonin transporter. The Journal of Pharmacology and Experimental Therapeutics 2005, 314(2):906-915.
22. Rang H.P. The kinetics of action of acetylcholine antagonists in smooth muscle. Proceedings of the Royal Society of London. Series B. Biological sciences 1966, 164(996):488-510.
23. Rudnick G., Wall S.C. The molecular mechanism of "ecstasy" [3, 4-methylenedioxy-methamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release. Proceedings of the National Academy of Sciences of the USA 1992, 89(5):1817-1821.
24. Segel I.H. Enzyme kinetics: Behavior and analysis of rapid equilbrium and steady-state enzyme systems 1975, Wiley and Sons, New York, US.
25. Singh S.K., Yamashita A., Gouaux E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 2007, 448(7156):952-956.
26. Sinning S., Musgaard M., Jensen M., Severinsen K., Celik L., Koldsoe H., et al. Binding and orientation of tricyclic antidepressants within the central substrate site of the human serotonin transporter. The Journal of Biological Chemistry 2009, published online November 30, 2009. 10.1074/jbc.M109.045401.
27. Stahl S.M., Grady M.M., Moret C., Briley M. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums 2005, 10(9):732-747.
28. Tavoulari S., Forrest L.R., Rudnick G. Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes. The Journal of Neuroscience 2009, 29(30):9635-9643.
29. Torres G.E., Gainetdinov R.R., Caron M.G. Plasma membrane monoamine transporters: Structure, regulation and function. Nature Reviews. Neuroscience 2003, 4(1):13-25.
30. Vaishnavi S.N., Nemeroff C.B., Plott S.J., Rao S.G., Kranzler J., Owens M.J. Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity. Biological Psychiatry 2004, 55(3):320-322.
31. Van Liefde I., Vauquelin G. Sartan-AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism. Molecular and Cellular Endocrinology 2009, 302(2):237-243.
32. Whitlock G.A., Andrews M.D., Brown A.D., Fish P.V., Stobie A., Wakenhut F. Design of monoamine reuptake inhibitors: SSRIs, SNRIs and NRIs. Topics in Medicinal Chemistry 2009, 4:53-94.
33. Zhou Z., Zhen J., Karpowich N.K., Goetz R.M., Law C.J., Reith M.E., et al. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 2007, 317(5843):1390-1393.
34. Zhou Z., Zhen J., Karpowich N.K., Law C.J., Reith M.E., Wang D.N. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nature Structural and Molecular Biology 2009, 16(6):652-657.